IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES

Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003

05 Aug 2021 08:00:02 By Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

13 Jul 2021 08:00:03 By Nasdaq GlobeNewswire

Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC

06 Jul 2021 08:00:01 By Nasdaq GlobeNewswire

Immutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings

21 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

21 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

Immutep Reveals a New Anti-LAG-3 Research Program

08 Jun 2021 08:00:01 By Nasdaq GlobeNewswire

Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021

04 Jun 2021 08:00:01 By Nasdaq GlobeNewswire

Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021

04 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor

02 Jun 2021 08:00:02 By Nasdaq GlobeNewswire

Immutep Enters Into A New Collaboration With Merck KGaA, Darmstadt, Germany For LAG-3 Therapy, Efti

01 Jun 2021 08:00:01 By Nasdaq GlobeNewswire